Sanofi's vaccine production facility to strengthen Singapore's future pandemic readiness

FRENCH healthcare company Sanofi broke ground for a vaccine production facility in Singapore on Wednesday (Apr 20), which is expected to create up to 200 local jobs, while providing greater and flexible vaccine production capacity.

The modular nature of this "evolutive vaccine facility" (EVF) makes it possible to produce 3 to 4 different vaccines simultaneously, in contrast to typical vaccine manufacturing facilities that can only produce 1 type of vaccine at a time.

This will enable more flexible manufacturing of multiple vaccines and biological platforms, including mRNA, enzymes and monoclonal antibodies, the company said in its press statement.